The Depo-Provera lawsuit 2026 litigation has reached its most consequential milestone yet: a global settlement in principle reached between Pfizer and plaintiffs’ lead counsel in June 2026 — before a single bellwether trial, before a Daubert ruling, and before a decision on preemption. As of August 2026, more than 6,200 lawsuits are pending in federal court. Pfizer and plaintiffs’ leadership signed a Master Settlement Agreement on July 21, 2026, though financial terms remain confidential and not every claim is covered. Pfizer estimates the proposed settlement could resolve approximately 80% of the pending MDL cases, while the remaining lawsuits will continue through the court process, including a hearing scheduled for September 2026. For anyone tracking MDL 3140, the next several months — covering settlement registration, causation hearings for non-settling claims, and the fate of state-court filings — are the most consequential in the history of this litigation.
The Depo-Provera MDL: Where Things Stand in August 2026
MDL 3140 was consolidated in the Northern District of Florida under Judge M. Casey Rodgers and has grown into one of the fastest-moving — and now most dramatically resolved — mass tort proceedings in the country. As of August 2026, over 6,294 claims have been consolidated in a multidistrict litigation (MDL), which is similar to a Depo-Provera class action lawsuit. That figure represents extraordinary growth: from March 2025 to March 2026, the litigation grew from 78 to 3,099 cases — a 3,873% increase in just one year. As of early 2026, plaintiffs’ lawyers reported holding nearly 10,000 unfiled claims, meaning the docket is likely to continue expanding even as the settlement process gets underway.
Monthly case management conferences have been held throughout 2026 at the U.S. District Courthouse in Pensacola, Florida, per the court’s pretrial orders. On March 6, 2026, the Court held its eleventh Case Management Conference in the litigation — a joint CMC held alongside the courts of New York and Delaware. Five pilot bellwether cases were selected to represent the broader plaintiff pool, including Blonski v. Pfizer — in which a patient who began using the drug in 2002 was later found to have developed two meningiomas — and Wilson v. Pfizer, where a woman who used Depo-Provera from 1998 to 2019 suffered a stroke that revealed a Grade 1 meningioma. The first bellwether trial, Toney v. Pfizer, had been set for December 7, 2026, but its deadlines were vacated after the settlement agreement was announced in June.
Women who suffered brain injuries linked to Depo-Provera use may want to use a brain injury calculator to get a preliminary sense of what their claim may be worth before consulting legal counsel.
The June 2026 Global Settlement: What It Does and Doesn’t Mean
In June 2026, Pfizer and attorneys representing thousands of women told a federal court they had reached a global settlement agreement in the Depo shot litigation — the most significant development in this case so far. On June 15, 2026, Judge M. Casey Rodgers announced in a court order that Pfizer and plaintiffs’ lead counsel have reached a global agreement to resolve eligible claims in the Depo-Provera MDL, though the terms have not yet been made public as both sides work to finalize the details. The Master Settlement Agreement was formally signed on July 21, 2026.
But the settlement news has been widely misunderstood. Some women diagnosed with meningioma brain tumors after using Depo-Provera now believe the case is over, that a single payout amount has been set, or that they’ve missed their chance to take legal action — none of that is true. The settlement is still being finalized, no financial terms have been announced, and new Depo shot claims are still being accepted.
Most pharmaceutical mass torts only settle after years of test trials called bellwethers. In this case, the agreement came before a single trial — and after two major developments strengthened the plaintiffs’ position: a 2024 BMJ study linking the shot to a more than 5-fold increase in meningioma risk, and the FDA’s December 2025 approval of a new U.S. warning label finally listing meningiomas as a risk. Together, these developments significantly increased pressure on Pfizer to resolve the claims before facing their first trial.
The settlement does not include cases filed in state courts, most of which are filed in New York and Delaware. Settlement registration is expected to be completed in November 2026. The claims review process and the first payments are expected to begin during the first quarter of 2027. The court also approved a no-fee administrative docket that will allow claims to enter the settlement review process without immediately paying a federal filing fee. The eligibility rules, settlement amounts, medical proof requirements, and payment tiers remain confidential. Each eligible plaintiff will decide whether to accept the settlement or opt out.
While a settlement has been tentatively reached for the Depo-Provera MDL, not all cases will be covered. Pfizer has filed a motion for new pilot cases to be selected to help work through the ongoing issues that could impact cases not covered in the agreement. After postponing the June 24–26 hearing, the court reset the causation and preemption hearing for July 27, 2026 — that hearing remains important because expert admissibility rulings will shape the trajectory of any claims that proceed to trial.
Pfizer’s Preemption Defense: Weakened But Not Dead
Pfizer’s preemption defense has been one of the central legal battles of MDL 3140. At the center of the litigation is Pfizer’s federal pre-emption defense. Pfizer argued that the FDA previously rejected proposed label changes related to meningioma risks, meaning state-law failure-to-warn claims should be dismissed. In 2024, Pfizer submitted a proposed label update to the FDA that would have included a meningioma warning. The FDA rejected this proposal after a nine-month review. Pfizer then used this rejection as the centerpiece of its legal defense — arguing that because the FDA said no, Pfizer cannot be held liable for failing to warn.
That defense took a severe blow in December 2025. On December 17, 2025, the U.S. Food and Drug Administration formally approved a meningioma brain tumor warning for Depo-Provera CI (medroxyprogesterone acetate injectable, 150 mg/mL) and Depo-SubQ Provera 104 — the first federal regulatory acknowledgment that a confirmed link exists between the birth control injection and intracranial tumors. For months, Pfizer’s primary legal argument — known as federal preemption — rested on the assertion that the FDA had previously reviewed and rejected a meningioma warning proposal, and therefore state-law failure-to-warn claims could not stand. The December 2025 label change directly dismantled that argument.
The FDA mandated a warning regarding the risk of meningioma for patients receiving medroxyprogesterone acetate injections. This update applies to both brand-name Depo-Provera and its authorized generic versions, including Greenstone, Viatris, and Prasco. Despite the settlement in principle, it remains unclear whether Pfizer’s preemption defense will be able to hold up following this critical development for the subset of claims that fall outside the settlement agreement.
Key MDL 3140 Statistics at a Glance
- Total federal claims as of August 2026: Over 6,294 claims consolidated in MDL 3140.
- Year-over-year growth: From March 2025 to March 2026, the litigation grew from 78 to 3,099 cases — a 3,873% increase in one year.
- Unfiled inventory: As of early 2026, plaintiffs’ lawyers reported holding nearly 10,000 unfiled claims.
- Settlement status: Pfizer and plaintiffs’ leadership signed a Master Settlement Agreement on July 21, 2026.
- Settlement coverage: Pfizer estimates the proposed settlement could resolve approximately 80% of pending MDL cases.
- First payment timeline: Settlement registration is expected to be completed in November 2026, with the first payments expected to begin during the first quarter of 2027.
- FDA label change: An FDA-ordered change to the Depo-Provera drug label added a meningioma warning in December 2025.
- Causation hearing: Judge Rodgers reset the general-causation and preemption hearing for July 27, 2026.
- State-court activity: In addition to the federal MDL, related cases are proceeding in various state courts, with reported activity in jurisdictions such as New York and Delaware.
Who Is Filing and What Are the Stakes?
Women can file a lawsuit as part of MDL 3140 if they were diagnosed with brain tumors (meningiomas) after taking the birth control shot. In their lawsuits, women allege that Depo-Provera’s active ingredient, medroxyprogesterone acetate (MPA), may increase a woman’s risk for developing hormone-sensitive brain tumors called meningiomas. Although these tumors are not typically cancerous, they can have several negative impacts on a woman’s health. Further allegations include that Pfizer knew or should have known about the potential increased tumor risk and failed to properly warn consumers.
The science underlying these claims has strengthened considerably. In March 2024, a British Medical Journal (BMJ) study examined the link between progestogens like medroxyprogesterone acetate and meningiomas. Researchers analyzed data from more than 18,000 women in France who underwent surgery for meningiomas between 2009 and 2018. Women who had used Depo-Provera for extended periods were over 5 times more likely to develop these tumors. More recently, in September 2025, a team of researchers from the Cleveland Clinic and Case Western Reserve University published findings in JAMA Neurology that provided the first large-scale U.S. data on the connection between Depo-Provera and meningioma. The study drew from the TriNetX database, a national network of 68 healthcare organizations, and analyzed records spanning from December 2004 to December 2024. Additionally, a July 2026 Danish study found that injectable medroxyprogesterone was associated with more than 4 times the odds of meningioma.
The range of plaintiffs is wide. A typical recent filing involves women who used Depo-Provera for years without any warning of the meningioma risk and who later experienced serious neurological symptoms. A Kansas plaintiff, for example, alleges that she received brand-name Depo-Provera injections from approximately 2021 through 2022 and developed symptoms in 2025 that included vertigo, dizziness, vision loss, and persistent headaches — and MRI and CT imaging later revealed an intracranial meningioma. The complaint alleges hearing loss, vision loss, persistent headaches, mental anguish, medical expenses, and other economic damages. The Depo-Provera brain tumor lawsuits allege negligent failure to warn, misrepresentation, and defective design. Women bringing Depo-Provera claims seek compensation for medical treatment, neurological damage, long-term disability, and pain and suffering caused by meningioma diagnoses.
What Plaintiffs and Claimants Should Know Right Now
The June 2026 settlement announcement does not mean the litigation is over or that every claimant is automatically protected. There are several critical action items for anyone affected by Depo-Provera:
- The settlement does not cover unfiled claims automatically. Women should not assume the settlement protects an unfiled claim, pauses the statute of limitations, or guarantees that a later filing will qualify.
- State-court claimants need separate attention. The available court materials do not establish that claims pending in Delaware, New York, or other state courts are included. Those plaintiffs may require separate agreements or procedures.
- Statutes of limitations are running. Statutes of limitations are now actively running for victims diagnosed in 2023 and early 2024, making immediate action more urgent than ever.
- New claims are still being accepted. Both sides recently agreed in principle to a global settlement for the Depo-Provera lawsuits that could resolve thousands of cases, but attorneys are still accepting new Depo-Provera cases and you or a loved one may be eligible.
- The FDA label change matters for your claim. The FDA’s December 2025 label change strengthens existing legal claims and may open the door for women who did not previously realize their tumor could be connected to the birth control shot.
- Prior Depo-Provera users remain eligible even after the label change. A woman who used Depo-Provera before December 2025 can file a new Depo-Provera lawsuit in 2026 alleging failure to warn about the meningioma side effect, regardless of whether their meningioma diagnosis was made before or after the December 2025 label change.
Frequently Asked Questions: Depo-Provera Lawsuit 2026
What is the June 2026 global settlement and does it cover my claim?
In June 2026, Pfizer and the plaintiffs’ leadership in the federal Depo-Provera litigation reached a global settlement in principle, according to an order entered June 15, 2026 by U.S. District Judge M. Casey Rodgers. The agreement would give eligible plaintiffs with cases pending in MDL-3140 an opportunity to resolve their claims. No financial terms were disclosed. While a settlement has been tentatively reached for the Depo-Provera MDL, not all cases will be covered. Pfizer has filed a motion for new pilot cases to be selected to help work through the ongoing issues that could impact cases not covered in the agreement. The major divider is cases that were filed into the MDL after March 27. Anyone who believes they may have a claim should consult an attorney promptly rather than waiting to see whether the settlement applies to them.
How many lawsuits have been filed in the Depo-Provera MDL as of August 2026?
As of August 2026, nearly 6,400 Depo-Provera lawsuits have been filed in federal court. The growth rate has been remarkable: as of early 2026, the MDL was seeing approximately 650 new lawsuits added each month, reflecting heightened awareness of the potential risks associated with the drug. In addition to the federal MDL, related cases are proceeding in various state courts, with reported activity in jurisdictions such as New York and Delaware. The litigation is formally captioned In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140.
What is Pfizer’s preemption defense and how could it affect my claim?
Pfizer argues that it cannot be blamed for failing to warn its customers of a meningioma risk associated with the Depo shot because the FDA rejected a label update in 2024 that would have included that information. But things changed in a big way in December 2025 when the FDA approved a new label for Depo that warns customers of a potential connection to meningiomas. This regulatory shift significantly weakens Pfizer’s preemption defense — their primary legal strategy — as the litigation moves forward. However, for claims that fall outside the settlement, the preemption question is not fully resolved. A ruling in favor of plaintiffs may allow those claims to proceed into broader discovery, expert development, bellwether preparation, and potential settlement discussions. A ruling for Pfizer, however, could significantly narrow or dismiss many pending claims.
What does the science say about Depo-Provera and meningioma risk?
The body of scientific evidence linking Depo-Provera to meningioma has grown substantially in recent years. In March 2024, a British Medical Journal (BMJ) study examined the link between progestogens like medroxyprogesterone acetate, the active ingredient in Depo shots, and meningiomas. Researchers analyzed data from more than 18,000 women in France who underwent surgery for meningiomas between 2009 and 2018. The study identified a 5.6-fold increased risk of intracranial meningioma among women using medroxyprogesterone acetate 150 mg injections for one year or more. No increased risk of meningioma was reported for women with less than one year of exposure, and around 75% of women who used Depo-Provera for more than a year had taken the medication for over 3 years.
A study published in JAMA Neurology in September 2025 found that women in the United States who use Depo-Provera may face a higher risk of developing meningioma. Researchers from the Cleveland Clinic and Case Western Reserve University analyzed data from more than 10 million women across 68 U.S. health care organizations between 2004 and 2024. They compared women who used different forms of hormonal contraception, including the Depo-Provera shot, oral contraceptives, and intrauterine devices (IUDs). A February 2025 University of British Columbia study reviewing records from more than 72,000 Depo-Provera users found women who received the injection for at least one year were 3.55 times more likely to develop intracranial meningiomas than women using oral contraceptive pills, and estimated that roughly one in every 1,111 women receiving the shot for a year may develop a tumor. A July 2026 Danish study also found that injectable medroxyprogesterone was associated with more than 4 times the odds of meningioma. Plaintiffs’ experts rely on these studies, as well as on decades of accumulating research linking progestins to meningioma growth — including earlier research that identified progesterone receptors in meningioma cells, work that plaintiffs argue Pfizer had access to long before any warning was issued.
What compensation amounts are being estimated for Depo-Provera lawsuit 2026 settlements?
No official payout figures from the Master Settlement Agreement have been made public. The eligibility rules, settlement amounts, medical proof requirements, and payment tiers remain confidential. However, attorneys tracking the litigation have offered general estimates based on comparable pharmaceutical mass torts. In other lawsuits involving meningiomas, settlement payouts have averaged more than $800,000, and jury verdicts have exceeded $3 million, according to the National Library of Medicine. King Law estimates potential settlement amounts in Depo-Provera cases to range between $150,000 and $500,000, while other anticipated settlements are expected to range between $100,000 and $5 million, depending on the circumstances of the case. Every case is different and depends on medical records, long-term use of Depo-Provera, and supporting evidence. Payouts will likely vary based on the severity of the tumor, the level of disability, and the strength of each claim. Many patients with meningiomas undergo expensive medical treatments like surgery or radiation, and Depo shot brain tumor settlements could potentially pay tens of thousands or even hundreds of thousands of dollars. Settlement registration is expected to be completed in November 2026, with the claims review process and first payments expected to begin in the first quarter of 2027.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.